52 results about "Intraepithelial neoplasia" patented technology

Objective methods for detecting and diagnosing prostate cancer (PRC) or prostatic intraepithelial neoplasia (PIN) are described herein. In one embodiment, the diagnostic method involves the determining an expression level of PRC-associated gene that discriminate between PRC or PIN and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of either or both of PRC and PIN, methods of treating either or both of PRC and PIN and method of vaccinating a subject against either or both of PRC and PIN.

Methods for treating, preventing, controlling the growth of and / or reducing the risk of developing cervical cancer, particularly in patients with cervical intraepithelial neoplasia are provided employing pharmaceutically acceptable preparations of DFMO. Methods for treating a patient having cervical intraepithelial neoplasia, which methods comprise administering DFMO alone or in combination with a cytotoxic or cytostatic agent, are also provided.

A method for differentiating cancerous lesions from surrounding tissue, which includes extracting an opacity parameter from acetowhite regions of pre acetic acid and post acetic acid images of a cervix.

The invention relates to non-surgical methods for treating cervical or vaginal neoplasia including cervical intraepithelial neoplasia, intraepithelial neoplasia, vulvar intraepithelial neoplasia and ano-genital warts. The treatment, which utilizes an effective amount of indole-3-carbinol and / or diindolylmethane, is effective whether or not the patient is also infected with human papillomavirus, the most common sexually transmitted viral disease in the United States and a known risk factor for both cervical intraepithelial neoplasia and cervical cancer.

The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.

A method for unsupervised classification of histological images of prostatic tissue includes providing histological image data obtained from a slide simultaneously co-stained with NIR fluorescent and Hematoxylin-and-Eosin (H&E) stains, segmenting prostate gland units in the image data, forming feature vectors by computing discriminating attributes of the segmented gland units, and using the feature vectors to train a multi-class classifier, where the classifier classifies prostatic tissue into benign, prostatic intraepithelial neoplasia (PIN), and Gleason scale adenocarcinoma grades 1 to 5 categories.

The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response.

Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).

The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response.

A method and composition for preventing prostate cancer and / or reducing PSA levels and / or alleviating the symptoms of BPH (Benign Prostatic Hyperplasia) or PIN (prostatic intraepithelial neoplasia) by administration of an effective amount of a mixture of flavopereirine and alstonine. A method and composition for treating low-grade prostate cancer and preventing the onset of metastatic disease and / or reducing the doubling time of PSA levels in men with positive biopsies showing relatively low Gleason scores and morphologies characteristic of non-invasive, slow-progressing prostate cancer. The flavopereirine and alstonine can be in the form of natural extracts derived from Pao Pereira and Rauwolfia Vomitoria, respectively. Alternatively, these two active compounds can be administered in purified form. The composition can be in included in a kit along with instructions for use in a treatment regimen.

This invention provides organic biomolecule markers (e.g., proteins) useful for differentiating prostate cancer, prostate intraepithelial neoplasia or benign prostate hyperplasia, from a negative diagnosis (i.e. normal and benign prostate epithelial cells).

The present invention relates to a cervical intraepithelial neoplasia model and the method of establishing model, which is characterized in that the cervical intraepithelial neoplasia tissue is embedded in the immunodeficiency mice to establish cervical intraepithelial neoplasia model. The method of establishing model is characterized in that the cervical intraepithelial neoplasia tissue is respectively taken from the biopsy under the vaginoscope and the tissues which are confirmed by the department of pathology and is inoculated subcutaneously in the back of the mice; the immunodeficiency mice of the present invention can overcome the xenoislet immune rejection reaction and receive the transplantation of the human tumor tissues, the tissue model after the transplantation has significant and stable character, short observation period and greater clinical reference significance of the experimental results. The present invention can explore the mechanism of the carcinogenesis of cervical carcinoma by outcome of the pathological process of CIN I, CIN II and CIN III animal models. Furthermore, by observing the period of the outcome of the cervical intraepithelial neoplasia tissue of the animal model, the present invention provides the feasible clinical animal experimental model for reversing the malignant transformation of the CIN I and CIN II lesion tissues.

The present invention is directed to a method of preventing cancer or preventing the recurrence of cancer after undergoing a cancer treatment by administering a composition comprising at least one of Gamma-tocotrienol or Gamma-tocotrienol, wherein the cancer is selected from the group consisting of melanoma, prostate cancer, prostate intraepithelial neoplasia, colon cancer, liver cancer, bladder cancer, breast cancer and lung cancer. The present invention is further directed to a composition comprising at least one of Gamma-tocotrienol or Delta-tocotrienol and Docetaxel and / or Dacarbazine, and to a method of inhibiting or arresting or reversing of cancer by administering a composition comprising at least one of Gamma-tocotrienol or Gamma-tocotrienol together with Docetaxel and / or Dacarbazine. The present invention is also directed to methods of manufacturing those compositions.

The invention discloses a plasma exosome miRNA molecular marker and an application thereof in a micro-digital PVR (polymerase chain reaction) kit for early diagnosis of cervical cancer. The RNA sequence of the molecular marker is shown in SEQ ID NO: 1-SEQU ID NO:8. Based on the marker, the detection has high sensitivity and specificity, and the AUC can be up to 0.992, and the diagnosis result is good. In the test data, samples of patients with intraepithelial neoplasia below grade 1 and above grade 2 can be effectively distinguished according to the expression levels of two miRNAs. The novel plasma exosome miRNA molecular marker has the characteristics of good diagnostic indicators, the diagnosis kit and the detection are used for detecting the 8 miRNAs, the kit is composed of specific amplification primers and general PRC amplification reagents and can be effectively used for screening and diagnosis of cervical cancer, and high clinical application and promotion value is achieved.

Physiologically acceptable films for use in the treatment cervical intraepithelial neoplasia are disclosed. The films include a water soluble film-forming polymer such as pullulan, and therapeutically effective amounts of chemexfoliation agents. Devices adapted to introduce these films to the cervix are disclosed, as well as various combinations of devices and films sufficient to comprise a kit to enable treatment of CIN 1, 2, and 3.

The invention provides methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer. The methods comprise the step of determining the expression levels or genetic status of specific miRNAs.

The present invention discloses a double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof, wherein the double-dyeing kit comprises an immunohistochemisty marker first antibody, and the immunohistochemisty marker first antibody is a mixed antibody reagent comprising Stathmin antibody and MCM2 antibody. With the application of the double-dyeing kit in the cervical intraepithelial neoplasia grading assisted diagnosis, the two immunohistochemisty markers are adopted as the mixed antibody so as to increase the sensitivity and the specificity of the CIN grading and accurately identifying the CIN grading; and the readability and the accuracy of the film reading are increased, the detection cost is reduced, and the operation steps are reduced.

Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.

Liposomes comprising an FKBP52 targeting agent (FTA) are disclosed. Pharmaceutical compositions comprising an FTA, a solvent, and a surfactant are disclosed. Pharmaceutical compositions comprising a cyclodextrin and / or a derivative thereof and an FTA are also disclosed. Method of detecting one or more compounds in a sample by liquid chromatography / tandem mass spectrometry (LC / MS / MS), methods of treating or preventing cancer, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostatitis, enlarged prostate, or insulin-independent diabetes, and methods of inhibiting spermatogenesis or fertilized oocyte implantation in a mammal are also provided.

The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.

The invention discloses a medical composition for preventing or treating pancreatic cancer and a reagent kit for detecting pancreatic cancer. The medical composition for preventing or treating pancreatic cancer can reduce or restrain (a) the biological activity of BCAT2 or (b) the expression of a BCAT2 coding gene. The invention relates to a reagent kit containing a reagent for detecting BCAT2. For the first time, the invention discloses that the BCAT2 can promote pancreatic cancer cell proliferation, and in vivo knockout of BCAT2 restrains pancreatic duct intraepithelial neoplasia (PanIN). The invention provides a medical composition for preventing and treating the pancreatic cancer, and a pancreatic cancer assessment reagent kit.

Low-coherence interferometry (LCI) techniques enable acquisition of structural and depth information of a sample. A “swept-source” (SS) light source may be used. The swept-source light source can be used to generate a reference signal and a signal directed towards a sample. Light scattered from the sample is returned as a result and mixed with the reference signal to achieve interference and thus provide structural information regarding the sample. Depth information about the sample can be obtained using Fourier domain concepts as well as time domain techniques. In another embodiment, an a / LCI system and method is provided that is based on a time domain system and employs a broadband light source. The systems and processes disclosed herein can be used for biomedical applications, included measuring cellular morphology in tissues and in vitro, as well as diagnosing intraepithelial neoplasia, and assessing the efficacy of chemopreventive and chemotherapeutic agents.

The invention discloses a Chinese medicine composition for performing postoperation cooperative treatment on mammary intraepithelial neoplasia. The Chinese medicine composition is prepared from Chinese angelica, white paeony roots, radix bupleuri, poria cocos, fried bighead atractylodes rhizome, green tangerine peels, dried tangerine peels, nutgrass galingale rhizome, szechwan Chinaberry fruits, pinellia ternate, rhizoma arisaematis, semen brassicae, snake gourd fruits, tangerine seeds, figwort roots, raw oyster shells, big fritillaria, spina gleditsiae, selfheal, weeping forsythiae capsule, Indian iphigenia bulbs, seaweed, sea-tent, rhizoma curculiginis and herba epimedii in a certain weight proportion, and has functions of promoting blood circulation and arresting pain, tretching liver to smooth qi, softening hard lump and dissipating stagnation and tuning up qi blood; and after the Chinese medicine composition can effectively treat the mammary intraepithelial neoplasia in a cooperative mode, common epithelium hyperplasia of a mammary duct is delayed and changed into atypical hyperplasia, preinvasive carcinoma and infiltrating carcinoma.

A method and composition for preventing prostate cancer and / or reducing PSA levels and / or alleviating the symptoms of BPH (Benign Prostatic Hyperplasia) or PIN (prostatic intraepithelial neoplasia) by administration of an effective amount of a mixture of flavopereirine and alstonine. A method and composition for treating low-grade prostate cancer and preventing the onset of metastatic disease and / or reducing the doubling time of PSA levels in men with positive biopsies showing relatively low Gleason scores and morphologies characteristic of non-invasive, slow-progressing prostate cancer. The flavopereirine and alstonine can be in the form of natural extracts derived from Pao Pereira and Rauwolfia Vomitoria, respectively. Alternatively, these two active compounds can be administered in purified form. The composition can be in included in a kit along with instructions for use in a treatment regimen.

The invention relates to a traditional Chinese medicine composition for treating chronic gastritis and gastric precancerous lesions. The traditional Chinese medicine composition is prepared from the raw materials: cablin potchouli herb, coptidis rhizoma, bran-stir-fried macrocephalae rhizoma, fructus amomi rotundus, scutellariae barbatae herba, herba hedyotidis, angelicae sinensis radix, chuanxiong rhizoma, notoginseng radix et rhizoma, poria, stir-fried radix paeoniae alba, bulbus oculi, bran-stir-fried aurantii fructus immaturus, prepared cyperus rotundus, aucklandiae radix, fructus amomi, scorpio and prepared corydalis rhizoma. The composition is prepared into pharmaceutically acceptable dosage forms by being added with pharmaceutically conventional auxiliary materials according to a pharmaceutically conventional process. The traditional Chinese medicine composition has a definite curative effect on chronic gastritis, chronic atrophic gastritis and gastric precancerous lesions (suchas intestinal metaplasia and intraepithelial neoplasia) in clinical symptoms, histopathology and molecular level, and is convenient to take, carry and store and low in cost.

The invention discloses application of a Chinese medicinal composition to treatment of stomach chronic inflammation with intestinal metaplasia and intraepithelial neoplasia. The Chinese medicinal composition mainly comprises a plurality of traditional Chinese medicines such as vietnamese sophora root, bistort rhizome, dahurian patrinia herb, root bark of shaggy-fruited dittany, common selfheal fruit-spike, airpotato yam rhizome and the like.

The invention discloses a pharmaceutical composition containing pokeberry antiviral proteins and an immunologic active material. The pharmaceutical composition comprises 0.001 to 10 wt% of pokeberry antiviral proteins and 0.1 to 60 wt% of immunologic active material, which is composed of one or more of algal polysaccharides, a cordyceps sinensis extract, a lucid ganoderma extract, propolis, aloe gel powder, polyinosinic acid-polycytidylic acid, and coconut oil. The pharmaceutical composition can effectively treat intraepithelial neoplasia of lower genital tracts of women and is a novel drug for the patients and doctors.